AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$AGIO

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agios (AGIO) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AGIONeutralMed
01

Why it matters

The earnings release offers fresh data on revenue growth, cash position, and pipeline milestones, informing valuation and trade decisions.

02

Market read

Earnings data may influence Agios stock and peers in the rare‑disease biotech space.

03

What to watch

Cost reductions from R&D headcount cuts may improve margins faster than expected

Relevance 7/10Novelty 7/10Timing: post-earnings release today

Background

Agios Pharmaceuticals held its Q3 2026 earnings call, reporting financial results and updates on its mitapivat program.

Company-level read

Ticker impact

$AGIONeutralHigh confidence
Context

Q3 2026 earnings results and guidance disclosed for the first time

Expected impact

neutral as market has likely priced in the results

Evidence & confidence

The transcript provides fresh financial numbers and operational updates that were not public before, but no dramatic guidance change or surprise catalyst to drive a strong directional move.

Market effects

Sector

Provides insight into biotech rare‑hematology sector performance and pipeline progress

Regional

Limited to US biotech investors

Global

Modest, as Agios is a niche player

Counterpoint

What could challenge this read

Potential upside if the FDA approval timeline for sickle‑cell indication accelerates

Key entities

  • company
    Agios Pharmaceuticals

    Biotech firm developing mitapivat for rare hematology diseases

Read at source← All news

StoryAgios reports Q3 2026 revenue surge and FDA review extension for mitapivat

Also covered by

5 outlets

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

tipranks.com
$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

finance.yahoo.com
$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

finance.yahoo.com
$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

investing.com
$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.

rttnews.com
$AGIOMed

What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

Agios Pharmaceuticals reported 177 new prescriptions in Q3, viewing it as a sustainable rate. The FDA extended its review of mitapivat for sickle cell disease to February 2027, requesting additional safety data. Agios plans to focus on 25,000 U.S. patients if approved. The company presented pipeline updates and expects to begin a phase II/III program for AG-236 by year-end. Q3 R&D expenses fell to $73.5M, while SG&A rose to $56.5M. Agios ended the quarter with $907M in cash.

finance.yahoo.com